Current and emerging drugs for the treatment of pruritus: an update of the literature

References

• Silverberg JI, Hinami K, Trick WE, et al. Itch in the general internal medicine setting: a cross-sectional study of prevalence and quality-of-life effects. Am J Clin Dermatol. 2016 Dec;17(6):681–690. doi: 10.1007/s40257-016-0215-3.
   PubMed Web of Science ®Google Scholar
• Vander Does A, Ju T, Mohsin N, et al. How to get rid of itching. Pharmacol Ther. 2023 Mar;243; 108355. doi: 10.1016/j.pharmthera.2023.108355.
   PubMed Web of Science ®Google Scholar
• Lay M, Dong X. Neural mechanisms of itch. Annu Rev Neurosci. 2020 Jul 8;43(1):187–205. doi: 10.1146/annurev-neuro-083019-024537.
   PubMedGoogle Scholar
• LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Rev Neurosci. 2014 Jan;15(1):19–31.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Kim B, Luger T, et al. Similarities and differences in peripheral itch and pain pathways in atopic dermatitis. J Allergy Clin Immunol. 2023 Dec 14; 153(4):904–912. doi: 10.1016/j.jaci.2023.10.034
   PubMedGoogle Scholar
• Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk.Immunity. 2020 May 19 52(5):753–766.doi: 10.1016/j.immuni.2020.04.008
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018 Nov;142(5):1375–1390. doi: 10.1016/j.jaci.2018.09.005.
   PubMed Web of Science ®Google Scholar
• Dong X, Dong X. Peripheral and central mechanisms of itch.Neuron. 2018 May 2 98(3):482–494.doi: 10.1016/j.neuron.2018.03.023
   PubMed Web of Science ®Google Scholar
• Shim WS, Tak MH, Lee MH, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci. 2007 Feb 28; 27(9):2331–2337. doi: 10.1523/JNEUROSCI.4643-06.2007
   PubMed Web of Science ®Google Scholar
• Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A. 2009 Jul 7; 106(27):11330–11335. doi: 10.1073/pnas.0905605106
   PubMed Web of Science ®Google Scholar
• Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007 Jan;119(1):176–183. doi: 10.1016/j.jaci.2006.08.034
   PubMed Web of Science ®Google Scholar
• Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H(4) receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 May;143(5):1830–1837 e4. doi: 10.1016/j.jaci.2018.07.047
   PubMed Web of Science ®Google Scholar
• Yang CC, Hung YL, Li HJ, et al. Quercetin inhibits histamine-induced calcium influx in human keratinocyte via histamine H4 receptors. Int Immunopharmacol. 2021 Jul;96:107620.
   PubMed Web of Science ®Google Scholar
• Roh YS, Choi J, Sutaria N, et al. Itch: epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022 Jan;86(1):1–14. doi: 10.1016/j.jaad.2021.07.076
   PubMed Web of Science ®Google Scholar
• Kittaka H, Tominaga M. The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin. Allergol Int. 2017 Jan;66(1):22–30.
   PubMed Web of Science ®Google Scholar
• Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011 May;14(5):595–602. doi: 10.1038/nn.2789
   PubMed Web of Science ®Google Scholar
• Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord.Nature. 2007 Aug 9 448(7154):700 3.doi: 10.1038/nature06029
   PubMed Web of Science ®Google Scholar
• Wan L, Jin H, Liu XY, et al. Distinct roles of NMB and GRP in itch transmission. Sci Rep. 2017 Nov 13; 7(1):15466. doi: 10.1038/s41598-017-15756-0
   PubMedGoogle Scholar
• Albisetti GW, Pagani M, Platonova E, et al. Dorsal horn gastrin-releasing peptide expressing neurons transmit spinal itch but not pain signals. J Neurosci. 2019 Mar 20; 39(12):2238–2250. doi: 10.1523/JNEUROSCI.2559-18.2019
   PubMed Web of Science ®Google Scholar
• Shiratori-Hayashi M, Koga K, Tozaki-Saitoh H, et al. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch. Nat Med. 2015 Aug;21(8):927–931. doi: 10.1038/nm.3912
   PubMed Web of Science ®Google Scholar
• Ross SE, Mardinly AR, McCord AE, et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron. 2010 Mar 25; 65(6):886–898. doi: 10.1016/j.neuron.2010.02.025
   PubMed Web of Science ®Google Scholar
• Potenzieri C, Undem BJ. Basic mechanisms of itch. Clin Exp Allergy. 2012 Jan;42(1):8–19.
   PubMed Web of Science ®Google Scholar
• Kardon AP, Polgar E, Hachisuka J, et al. Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron. 2014 May 7; 82(3):573–586. doi: 10.1016/j.neuron.2014.02.046
   PubMed Web of Science ®Google Scholar
• Bourane S, Duan B, Koch SC, et al. Gate control of mechanical itch by a subpopulation of spinal cord interneurons. Science. 2015 Oct 30; 350(6260):550–554. doi: 10.1126/science.aac8653
   PubMed Web of Science ®Google Scholar
• Mu D, Deng J, Liu KF, et al. A central neural circuit for itch sensation. Science. 2017 Aug 18; 357(6352):6352):695–699. doi: 10.1126/science.aaf4918
   Web of Science ®Google Scholar
• Papoiu AD, Coghill RC, Kraft RA, et al. A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch. Neuroimage. 2012 Feb 15; 59(4):3611–3623. doi: 10.1016/j.neuroimage.2011.10.099
   PubMed Web of Science ®Google Scholar
• Misery L, Dutray S, Chastaing M, et al. Psychogenic itch. Transl Psychiatry. 2018 Mar;8(1):52. doi: 10.1038/s41398-018-0097-7
   PubMed Web of Science ®Google Scholar
• Orliaguet M, Brenaut E, Ficheux AS, et al. Psychogenic and neurogenic components in patients with psychogenic or neuropathic pruritus: PRURINEURO: a non-interventional single-centre prospective assay. Skin Health Dis. 2023 Jul; 3(6):e267. doi: 10.1002/ski2.267
   PubMedGoogle Scholar
• Akiyama T, Lerner EA, Carstens E. Protease-activated receptors and itch. Handb Exp Pharmacol. 2015;226:219–235.
   PubMedGoogle Scholar
• Varricchi G, Pecoraro A, Loffredo S, et al. Heterogeneity of human mast cells with respect to MRGPRX2 receptor expression and function. Front Cell Neurosci. 2019;13:299.
   PubMed Web of Science ®Google Scholar
• Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol. 2014 Sep;134(3):622–633 e9. doi: 10.1016/j.jaci.2014.05.004
   PubMed Web of Science ®Google Scholar
• Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018 Jun;138(6):1311–1317. doi: 10.1016/j.jid.2017.12.029
   PubMed Web of Science ®Google Scholar
• Nattkemper LA, Fourzali K, Yosipovitch G. Cutaneous gene expression in primates with itch. J Invest Dermatol. 2021 Jun;141(6):1586–1588.
   PubMed Web of Science ®Google Scholar
• Alam M, Buddenkotte J, Ahmad F, et al. Neurokinin 1 receptor antagonists for pruritus. Drugs. 2021 Apr;81(6):621–634. doi: 10.1007/s40265-021-01478-1
   PubMed Web of Science ®Google Scholar
• Amatya B, El-Nour H, Holst M, et al. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol. 2011 May;164(5):1023–1029. doi: 10.1111/j.1365-2133.2011.10241.x
   PubMed Web of Science ®Google Scholar
• Ohanyan T, Schoepke N, Eirefelt S, et al. Role of substance p and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derm Venereol. 2018 Jan 12; 98(1):26–31. doi: 10.2340/00015555-2780
   PubMed Web of Science ®Google Scholar
• Kim BS, Inan S, Stander S, et al. Role of kappa-opioid and mu-opioid receptors in pruritus: peripheral and central itch circuits. Exp Dermatol. 2022 Dec;31(12):1900–1907. doi: 10.1111/exd.14669
   PubMed Web of Science ®Google Scholar
• Misery L, Pierre O, Le Gall-Ianotto C, et al. Basic mechanisms of itch. J Allergy Clin Immunol. 2023 Jul;152(1):11–23. doi: 10.1016/j.jaci.2023.05.004
   PubMed Web of Science ®Google Scholar
• Sousa-Valente J, Andreou AP, Urban L, et al. Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. Br J Pharmacol. 2014 May;171(10):2508–2527. doi: 10.1111/bph.12532
   PubMed Web of Science ®Google Scholar
• Palkar R, Ongun S, Catich E, et al. Cooling relief of acute and chronic itch requires TRPM8 channels and neurons. J Invest Dermatol. 2018 Jun;138(6):1391–1399. doi: 10.1016/j.jid.2017.12.025
   PubMed Web of Science ®Google Scholar
• Gouin O, L’Herondelle K, Lebonvallet N, et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell. 2017 Sep;8(9):644–661. doi: 10.1007/s13238-017-0395-5
   PubMed Web of Science ®Google Scholar
• Wilson SR, Nelson AM, Batia L, et al. The ion channel TRPA1 is required for chronic itch. J Neurosci. 2013 May 29; 33(22):9283–9294. doi: 10.1523/JNEUROSCI.5318-12.2013
   PubMed Web of Science ®Google Scholar
• Biro T, Kovacs L. An “ice-cold” TR(i)P to skin biology: the role of TRPA1 in human epidermal keratinocytes. J Invest Dermatol. 2009 Sep;129(9):2096–2099.
   PubMed Web of Science ®Google Scholar
• Nattkemper LA, Lipman ZM, Ingrasci G, et al. Neuroimmune mediators of pruritus in Hispanic scalp psoriatic itch. Acta Derm Venereol. 2023 Mar 23; 103:adv4463. doi: 10.2340/actadv.v103.4463
   PubMed Web of Science ®Google Scholar
• Akiyama T, Ivanov M, Nagamine M, et al. Involvement of TRPV4 in serotonin-evoked scratching. J Invest Dermatol. 2016 Jan;136(1):154–160. doi: 10.1038/JID.2015.388
   PubMed Web of Science ®Google Scholar
• Domingo S, Sole C, Moline T, et al. MicroRNAs in several cutaneous autoimmune diseases: psoriasis, cutaneous lupus erythematosus and atopic dermatitis. Cells. 2020 Dec;9(12):2656.
   PubMed Web of Science ®Google Scholar
• Han Q, Liu D, Convertino M, et al. miRNA-711 binds and activates TRPA1 extracellularly to evoke acute and chronic pruritus. Neuron. 2018;99(3):449–463 e446. doi: 10.1016/j.neuron.2018.06.039
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang ZL, Yeo M, et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology. 2021;161(1):301–317 e316. doi: 10.1053/j.gastro.2021.03.049
   PubMed Web of Science ®Google Scholar
• De Logu F, Maglie R, Titiz, et al. miRNA-203b-3p induces acute and chronic pruritus through 5-HTR2B and TRPV4. J Invest Dermatol. 2023;143(1):142–153 e110. doi: 10.1016/j.jid.2022.08.034
   PubMed Web of Science ®Google Scholar
• Kuhn H, Kappes L, Wolf K, et al. Complementary roles of murine Na(V)1.7, Na(V)1.8 and Na(V)1.9 in acute itch signalling. Sci Rep. 2020 Feb 11; 10(1):2326. doi: 10.1038/s41598-020-59092-2
   PubMed Web of Science ®Google Scholar
• Devigili G, Eleopra R, Pierro T, et al. Paroxysmal itch caused by gain-of-function Nav1.7 mutation. Pain. 2014 Sep;155(9):1702–1707. doi: 10.1016/j.pain.2014.05.006
   PubMed Web of Science ®Google Scholar
• Salvatierra J, Diaz-Bustamante M, Meixiong J, et al. A disease mutation reveals a role for NaV1.9 in acute itch. J Clin Invest. 2018 Dec 3; 128(12):5434–5447. doi: 10.1172/JCI122481
   PubMed Web of Science ®Google Scholar
• Du LX, Zhu JY, Mi WL. Cytokines and chemokines modulation of itch. Neuroscience. 2022 Jul 15; 495:74–85. doi: 10.1016/j.neuroscience.2022.05.035
   PubMed Web of Science ®Google Scholar
• Ingrasci G, Lipman ZM, Hawash AA, et al. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp Dermatol. 2021 Sep;30(9):1208–1217. doi: 10.1111/exd.14401
   PubMed Web of Science ®Google Scholar
• Garcovich S, Maurelli M, Gisondi P, et al. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021 Mar 23;9(3). doi: 10.3390/vaccines9030303
   PubMed Web of Science ®Google Scholar
• Han Y, Woo YR, Cho SH, et al. Itch and janus kinase inhibitors. Acta Derm Venereol. 2023 Feb 15;103:adv00869).
   PubMed Web of Science ®Google Scholar
• Chapman S, Kwa M, Gold LS, et al. Janus kinase inhibitors in dermatology: part I. A comprehensive review. J Am Acad Dermatol. 2022 Feb;86(2):406–413. doi: 10.1016/j.jaad.2021.07.002
   PubMedGoogle Scholar
• Mahmoud O, Oladipo O, Mahmoud RH, et al. Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch. Front Mol Neurosci. 2023;16:1272230. doi: 10.3389/fnmol.2023.1272230.
   PubMed Web of Science ®Google Scholar
• de Jong Ec, Vieira PL, Kalinski P, et al. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol. 1999 Aug;66(2):201–204. doi: 10.1002/jlb.66.2.201
   PubMed Web of Science ®Google Scholar
• Gutfreund K, Bienias W, Szewczyk A, et al. Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013 Jun;30(3):165–169. doi: 10.5114/pdia.2013.35619
   PubMed Web of Science ®Google Scholar
• Lipman ZM, Labib A, Yosipovitch G. Current clinical options for the management of itch in atopic dermatitis. Clin Cosmet Investig Dermatol. 2021;14:959–969.
   PubMed Web of Science ®Google Scholar
• Mahmoud O, Soares GB, Yosipovitch G. Transient receptor potential channels and itch.Int J Mol Sci. 2022 Dec 27 24(1):420.doi: 10.3390/ijms24010420
   PubMed Web of Science ®Google Scholar
• Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a ‘hot’ medicine is reignited. Expert Opin Pharmacother. 2010 Jun;11(8):1359–1371.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019 May 1; 155(5):585–593. doi: 10.1001/jamadermatol.2019.0008
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Simpson EL, Tan H, et al. Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials. Itch. 2018;3(2):e12–e12. doi: 10.1097/itx.0000000000000012
   Google Scholar
• Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018 Apr 27; 98(5):484–489. doi: 10.2340/00015555-2893
   PubMed Web of Science ®Google Scholar
• A proof of concept clinical trial evaluating the safety and efficacy of Eucrisa (crisaborole) in patients with mild to moderate seborrheic dermatitis.
   Google Scholar
• Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022 Sep 20; 328(11):1073–1084. doi: 10.1001/jama.2022.15632
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Draelos ZD, Stein Gold L, et al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024 Jan 20; 90(5):986–993. doi: 10.1016/j.jaad.2023.12.065
   PubMedGoogle Scholar
• Eichenfield L, Boguniewicz M, Simpson E, et al. Once-Daily Roflumilast Cream 0.15% For Atopic Dermatitis: Pooled results: from Integument-1/2 phase 3 trials. Ann Allergy Asthma Immunol. 2023 Nov;131(5):S91. doi: 10.1016/j.anai.2023.08.273
   Web of Science ®Google Scholar
• van den Bogaard EH, Bergboer JGM, Vonk-Bergers JG, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013 Feb;123(2):917–927. doi: 10.1172/JCI65642
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021 Apr;84(4):1059–1067. doi: 10.1016/j.jaad.2020.10.085
   PubMed Web of Science ®Google Scholar
• Trial of VTAMA® (tapinarof) cream, 1% once daily in adults and children as young as 2 years old [Internet].
   Google Scholar
• Dermavant reports positive topline results from adoring 1, the second atopic dermatitis phase 3 trial of VTAMA® (tapinarof) cream, 1% in adults and children as young as 2 years old. Business Wire [Internet].
   Google Scholar
• Dermavant announces positive data from the adoring phase 3 development program in atopic dermatitis with VTAMA® (tapinarof) cream, 1% in adults and children as young as 2 years old [Internet]. https://www.biospace.com/article/releases/dermavant-announces-positive-data-from-the-adoring-phase-3-development-program-in-atopic-dermatitis-with-vtama-tapinarof-cream-1-percent-in-adults-and-children-as-young-as-2-years-old/.
   Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863–872. doi: 10.1016/j.jaad.2021.04.085
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Kircik L, Papp KA, et al. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):137–146. doi: 10.1111/jdv.18571
   PubMed Web of Science ®Google Scholar
• Landis MN, Arya M, Smith S, et al. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol. 2022 Dec;187(6):878–887. doi: 10.1111/bjd.21826
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020 Apr;82(4):823–831. doi: 10.1016/j.jaad.2019.12.015
   PubMed Web of Science ®Google Scholar
• Kursewicz C, Valdes-Rodriguez R, Yosipovitch G. Methotrexate in the treatment of chronic itch in the geriatric population. Acta Derm Venereol. 2020 Jan 23;100(1):adv00037.
   PubMed Web of Science ®Google Scholar
• Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018 Jun;19(3):319–332.
   PubMed Web of Science ®Google Scholar
• Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: a retrospective review. J Am Acad Dermatol. 2015 Sep;73(3):439–443.
   PubMed Web of Science ®Google Scholar
• Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, et al. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020 Nov-Dec;95(6):731–736. doi: 10.1016/j.abd.2020.05.003
   PubMed Web of Science ®Google Scholar
• Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2–3):119–125.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Le Roy Y, Ficheux AS, Misery L, et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: a systematic literature review and meta-analysis. Front Med (Lausanne). 2022 Dec;9:1079323.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Misery L, Clibborn C, et al. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi: 10.1002/cti2.1390
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Kaplan MH. STAT6 and PARP family members in the development of t cell-dependent allergic inflammation. Immune Netw. 2016 Aug;16(4):201–210.
   PubMed Web of Science ®Google Scholar
• Mack MR, Miron Y, Chen F, et al. Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli. Front Mol Neurosci. 2023;16:1258823.
   PubMed Web of Science ®Google Scholar
• Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1659–1661 e1.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020 Jun;82(6):1328–1336. doi: 10.1016/j.jaad.2020.02.060
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Mollanazar N, Stander S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023 May;29(5):1180–1190. doi: 10.1038/s41591-023-02320-9
   PubMed Web of Science ®Google Scholar
• Cao P, Xu W, Jiang S, et al. Dupilumab for the treatment of prurigo nodularis: a systematic review. Front Immunol. 2023;14:1092685.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Armstrong A, Guttman-Yassky E, et al. Real-world effectiveness of dupilumab in atopic dermatitis patients: analysis of an electronic medical records dataset. Dermatol Ther (Heidelb). 2022;12(6):1337–1350. doi: 10.1007/s13555-022-00731-z
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uremic pruritus. JAAD Case Rep. 2019 April;5(4):339–341.
   PubMedGoogle Scholar
• Huang D, Zhang Y, Yu Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol. 2023 Dec;125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157
   PubMedGoogle Scholar
• Jeon J, Wang F, Badic A, et al. Treatment of patients with chronic pruritus of unknown origin with dupilumab. J Dermatolog Treat. 2022 May;33(3):1754–1757.
   PubMed Web of Science ®Google Scholar
• Fournier C, Hirsch I, Spreafico A, et al. Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: a case series and review of the literature. SAGE Open Med Case Rep. 2023 Aug;11:2050313X231195462.
   PubMed Web of Science ®Google Scholar
• Talmon A, Elias S, Rubin L, et al. Dupilumab for cancer-associated refractory pruritus. J Allergy Clin Immunol Glob. 2023 Jun 2(3):100128. DOI:10.1016/j.jacig.2023.100128
   PubMedGoogle Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437–449. doi: 10.1111/bjd.19574
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450–463. doi: 10.1111/bjd.19573
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Lio PA, Rosmarin D, et al. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2024 Jan 23;190(2):289–291.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Thaci D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023 Mar 23; 388(12):1080–1091. doi: 10.1056/NEJMoa2206714
   PubMed Web of Science ®Google Scholar
• Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023 Feb 1;159(2):182–191.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Soung J, Weiss J, et al. Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. Acta Derm Venereol. 2019 Jul 1;99(9):820–821.
   PubMed Web of Science ®Google Scholar
• Honma M, Kanai Y, Murotani K, et al. Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: the ProLOGUE study. J Dermatol. 2023 Apr;50(4):453–461.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reich A, Steinhoff M, et al. Impact of ixekizumab treatment on itch and psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis: an integrated analysis of two phase III randomized studies. Dermatol Ther (Heidelb). 2018 Dec;8(4):621–637. doi: 10.1007/s13555-018-0267-9
   PubMed Web of Science ®Google Scholar
• Merola JF, Ghislain PD, Dauendorffer JN, et al. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1257–1262. doi: 10.1111/jdv.16181
   PubMed Web of Science ®Google Scholar
• Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:638325.
   PubMed Web of Science ®Google Scholar
• Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus.Sci Transl Med. 2021 Nov 10 13(619):eabe3037.doi: 10.1126/scitranslmed.abe3037
   PubMed Web of Science ®Google Scholar
• Crunkhorn, S Oncostatin M blockade alleviates itch. Nat Rev Drug Discov. 2022 Jan;21(1):20.
   Web of Science ®Google Scholar
• Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis [Internet]. Galderma
   Google Scholar
• Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Mar;57:101826.
   PubMedGoogle Scholar
• Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023 Oct 25; 189(5):531–539. doi: 10.1093/bjd/ljad240
   PubMed Web of Science ®Google Scholar
• Le AM, Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab.Pharmaceutics. 2022 Dec 8 14(12):2753.doi: 10.3390/pharmaceutics14122753
   PubMed Web of Science ®Google Scholar
• Terhorst-Molawi D, Hawro T, Grekowitz E, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023 May;78(5):1269–1279. doi: 10.1111/all.15585
   PubMed Web of Science ®Google Scholar
• Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022 Aug;77(8):2393–2403. doi: 10.1111/all.15262
   PubMed Web of Science ®Google Scholar
• Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton’s tyrosine kinase inhibition-an emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022 Aug;77(8):2355–2366. doi: 10.1111/all.15261
   PubMed Web of Science ®Google Scholar
• Gimeno R, Ribas-Llaurado C, Pesque D, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcepsilonR1 expression level and omalizumab clinical response. Clin Transl Allergy. 2023 Mar;13(3):e12227. doi: 10.1002/clt2.12227
   PubMed Web of Science ®Google Scholar
• Maurer M, Berger W, Gimenez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Dec;150(6):1498–1506 e2. doi: 10.1016/j.jaci.2022.08.027
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024 Jan;17(1):e13688. doi: 10.1111/cts.13688
   PubMed Web of Science ®Google Scholar
• Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and ad up randomized clinical trials. JAMA Dermatol. 2023 May 1;159(5):526–535.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, de Bruin-Weller M, Calimlim, et al. Aggregate response benefit in skin clearance and itch reduction with upadacitinib or dupilumab in patients with moderate-to-severe atopic dermatitis. Dermatitis. 2023 Dec. doi: 10.1089/derm.2023.0153
   Web of Science ®Google Scholar
• Ibba L, Gargiulo L, Vignoli CA, et al. Practical use of upadacitinib in patients with severe atopic dermatitis in a real-world setting: a systematic review. Clin Cosmet Investig Dermatol. 2024 Mar;17:593–604.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Jul 25; 396(10246):255–266. doi: 10.1016/S0140-6736(20)30732-7
   PubMed Web of Science ®Google Scholar
• Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 Aug;87(2):351–358. doi: 10.1016/j.jaad.2022.04.009
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021 Sep 1; 157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Heliyon. 2023 Jun;9(6):e16704.
   PubMed Web of Science ®Google Scholar
• Wollam J, Solomon M, Villescaz C, et al. MRGPRX2 antagonist EP262 potently inhibits agonist-induced mast cell degranulation in vitro and in vivo. J Allergy Clin Immunol. 2023;151(2):AB203. doi: 10.1016/j.jaci.2022.12.634
   Web of Science ®Google Scholar
• Cao C, Kang HJ, Singh I, et al. Structure, function and pharmacology of human itch GPCRs. Nature. 2021 Dec;600(7887):170–175. doi: 10.1038/s41586-021-04126-6
   PubMed Web of Science ®Google Scholar
• Escient pharmaceuticals announces positive results from phase 1 study of ep262, a first-in-class oral MRGPRX2 antagonist for mast cell mediated disorders [Internet].
   Google Scholar
• Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan Med Surg. 2011 Jun;30(2):118–126.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Das A, Hassanandani T, et al. Topical pramoxine in chronic pruritus: where do we stand? Indian J Dermatol. 2021 Sep-Oct;66(5):576. doi: 10.4103/ijd.ijd_1_21
   PubMed Web of Science ®Google Scholar
• Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg. 2009 Mar;108(3):837–845.
   PubMed Web of Science ®Google Scholar
• Andersen HH, Arendt-Nielsen L, Elberling J. Topical capsaicin 8% for the treatment of neuropathic itch conditions. Clin Exp Dermatol. 2017 Jul;42(5):596–598.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G. The 8% capsaicin - a hot medicine for neuropathic itch. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1403.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, et al. The role and mechanism of action of menthol in topical analgesic products. J Clin Pharm Ther. 2018 Jun;43(3):313–319. doi: 10.1111/jcpt.12679
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang H, Wang Y, et al. The distinctive role of menthol in pain and analgesia: mechanisms, practices, and advances. Front Mol Neurosci. 2022;15:1006908.
   PubMed Web of Science ®Google Scholar
• Park CW, Kim BJ, Lee YW, et al. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). J Allergy Clin Immunol. 2022 Apr;149(4):1340–1347 e4. doi: 10.1016/j.jaci.2021.09.024
   PubMed Web of Science ®Google Scholar
• Fowler E, Yosipovitch G. Chronic itch management: therapies beyond those targeting the immune system. Ann Allergy Asthma Immunol. 2019 Aug;123(2):158–165.
   PubMed Web of Science ®Google Scholar
• Papoiu AD, Valdes-Rodriguez R, Nattkemper LA, et al. A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol. 2013 Sep 4;93(5):520–526.
   PubMed Web of Science ®Google Scholar
• Developing a novel topical drug to alleviate neuropathic itch https://www.clexio.com/pipeline/cle-400-pruritus/
   Google Scholar
• Barr TP, Garzia C, Guha S, et al. PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol. 2019 Feb;139(2):412–421. doi: 10.1016/j.jid.2018.08.019
   PubMed Web of Science ®Google Scholar
• Cao T, Tan ES, Chan YH, et al. Anti-pruritic efficacies of doxycycline and erythromycin in the treatment of acne vulgaris: a randomized single-blinded pilot study. Indian J Dermatol Venereol Leprol. 2018 Jul-Aug;84(4):458–460. doi: 10.4103/ijdvl.IJDVL_41_17
   PubMed Web of Science ®Google Scholar
• Bohannon M, Liu M, Nadeau P, et al. Topical doxycycline monohydrate hydrogel 1% targeting proteases/PAR2 pathway is a novel therapeutic for atopic dermatitis. Exp Dermatol. 2020 Dec;29(12):1171–1175. doi: 10.1111/exd.14201
   PubMed Web of Science ®Google Scholar
• Fowler E, Yosipovitch G. A new generation of treatments for itch.Acta Derm Venereol. 2020 Jan 7 100(2):adv00027.doi: 10.2340/00015555-3347
   PubMedGoogle Scholar
• Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther. 2008 Jan-Feb;21(1):32–41.
   PubMed Web of Science ®Google Scholar
• Simonsen E, Komenda P, Lerner B, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017 Nov;70(5):638–655. doi: 10.1053/j.ajkd.2017.05.018
   PubMed Web of Science ®Google Scholar
• Eusebio-Alpapara KMV, Castillo RL, Dofitas BL. Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. Int J Dermatol. 2020 Apr;59(4):412–422.
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006 Feb 21; 12(7):1125–1128. doi: 10.3748/wjg.v12.i7.1125
   PubMed Web of Science ®Google Scholar
• Meridor K, Berookhim J, Levy Y. Low dose naloxone for pruritus in systemic sclerosis: case series and literature review.Medicine (Baltimore). 2022 Jan 28 101(4):e28653.doi: 10.1097/MD.0000000000028653
   PubMed Web of Science ®Google Scholar
• Pereira MP, Zeidler C, Stander S. Improvement of chronic kidney disease-associated pruritus after treatment with intravenous naloxone.JAMA Dermatol. 2021 Nov 1 157(11):1380–1381.doi: 10.1001/jamadermatol.2021.3829
   PubMed Web of Science ®Google Scholar
• Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006 Mar;54(3):527–531.
   PubMed Web of Science ®Google Scholar
• Labib A, Ju T, Lipman ZM, et al. Evaluating the effectiveness of intranasal butorphanol in reducing chronic itch. Acta Derm Venereol. 2022 Jun 9;102:adv00729. doi: 10.2340/actadv.v102.2153
   PubMed Web of Science ®Google Scholar
• Khanna R, Kwon CD, Patel SP, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol. 2020 Nov;83(5):1529–1533. doi: 10.1016/j.jaad.2020.07.017
   PubMed Web of Science ®Google Scholar
• Positive topline results from Japanese phase III clinical study (double-blind period) of difelikefalin (MR13A9) in hemodialysis patients with pruritus [Internet].
   Google Scholar
• Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020 Jan 16; 382(3):222–232. doi: 10.1056/NEJMoa1912770
   PubMed Web of Science ®Google Scholar
• Fishbane S, Wen W, Munera C, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med. 2022 Aug;4(8):100513. doi: 10.1016/j.xkme.2022.100513
   PubMedGoogle Scholar
• Yosipovitch G, Awad A, Spencer RH, et al. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. J Am Acad Dermatol. 2023 Apr 12;89(2):261–268.
   PubMed Web of Science ®Google Scholar
• Kim BS, Bissonnette R, Nograles K, et al. Phase 2 trial of difelikefalin in notalgia paresthetica. N Engl J Med. 2023 Feb 9; 388(6):511–517. doi: 10.1056/NEJMoa2210699
   PubMed Web of Science ®Google Scholar
• Besner Morin C, Misery L. Emerging treatments and novel pathways in pruritus. J Cutan Med Surg. 2019 Sep/Oct;23(5):528–536.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Bernhard JD, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):453–461. doi: 10.1111/jdv.17816
   PubMed Web of Science ®Google Scholar
• Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol. 2017;46(6):450–458. doi: 10.1159/000484573
   PubMed Web of Science ®Google Scholar
• Stander S, Bockenholt B, Schurmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45–51. doi: 10.2340/00015555-0553
   PubMed Web of Science ®Google Scholar
• Patel P, Patel K, Pandher K, et al. The role of psychiatric, analgesic, and antiepileptic medications in chronic pruritus. Cureus. 2021 Aug;13(8):e17260.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007 Mar;45(3):666–674. doi: 10.1002/hep.21553
   PubMed Web of Science ®Google Scholar
• Boozalis E, Khanna R, Kwatra SG. Selective serotonin reuptake inhibitors for the treatment of chronic pruritus. J Dermatolog Treat. 2018 Dec;29(8):812–814.
   PubMed Web of Science ®Google Scholar
• Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother. 2010 Jul;11(10):1673–1682.
   PubMed Web of Science ®Google Scholar
• Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004 Jun;50(6):889–891.
   PubMed Web of Science ®Google Scholar
• Khanna R, Boozalis E, Belzberg M, et al. Mirtazapine for the Treatment of Chronic Pruritus. Medicines (Basel). 2019 Jul 6;6(3).73
   PubMedGoogle Scholar
• Shao K, Stewart C, Grant-Kels JM. Cannabis and the skin. Clin Dermatol. 2021 Sep-Oct;39(5):784–795.
   PubMed Web of Science ®Google Scholar
• Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002 Aug;97(8):2117–2119. doi: 10.1111/j.1572-0241.2002.05852.x
   PubMed Web of Science ®Google Scholar
• Morin CB, Raef HS, Elmariah SB. Neuropathic itch treated with oral cannabinoids: a case series. JAAD Case Rep. 2021 Nov;17:38–42.
   PubMedGoogle Scholar
• Kwatra SG, Kambala A, Cornman H, et al. Ketamine infusions for treatment-resistant neuropathic pruritus. JAMA Dermatol. 2023 Sep 1; 159(9):1011–1012. doi: 10.1001/jamadermatol.2023.1772
   PubMed Web of Science ®Google Scholar
• Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and Management of Neuropathic Itch. Dermatol Clin. 2018 Jul;36(3):213–224.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Mishra SK, Olivry T, et al. Periostin, an emerging player in itch sensation. J Invest Dermatol. 2021 Oct;141(10):2338–2343. doi: 10.1016/j.jid.2021.03.009
   PubMed Web of Science ®Google Scholar